Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells $218,099.34 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) COO Christina Rossi sold 2,274 shares of the company's stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $95.91, for a total transaction of $218,099.34. Following the transaction, the chief operating officer now owns 69,383 shares in the company, valued at approximately $6,654,523.53. The trade was a 3.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Christina Rossi also recently made the following trade(s):

• On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $95.10, for a total transaction of $216,257.40.

Blueprint Medicines Stock Up 1.4 %

Shares of BPMC traded up $1.21 during mid-day trading on Friday, hitting $90.14. 1,267,436 shares of the company's stock were exchanged, compared to its average volume of 690,807. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. Blueprint Medicines Co. has a 52 week low of $72.24 and a 52 week high of $121.90. The company has a market cap of $5.73 billion, a PE ratio of -42.72 and a beta of 0.59. The company has a 50-day simple moving average of $92.45 and a 200 day simple moving average of $97.23.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating analysts' consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. During the same quarter last year, the firm earned ($2.20) earnings per share. The firm's revenue for the quarter was up 126.5% compared to the same quarter last year. On average, research analysts forecast that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Institutional Trading of Blueprint Medicines

Hedge funds and other institutional investors have recently modified their holdings of the stock. Raymond James & Associates grew its stake in Blueprint Medicines by 45.2% in the second quarter. Raymond James & Associates now owns 13,550 shares of the biotechnology company's stock valued at $1,460,000 after purchasing an additional 4,215 shares in the last quarter. EFG Asset Management North America Corp. increased its holdings in Blueprint Medicines by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 27,884 shares of the biotechnology company's stock worth $3,008,000 after buying an additional 132 shares during the last quarter. Bank of New York Mellon Corp raised its position in Blueprint Medicines by 13.6% during the second quarter. Bank of New York Mellon Corp now owns 273,930 shares of the biotechnology company's stock worth $29,524,000 after acquiring an additional 32,740 shares in the last quarter. Legato Capital Management LLC acquired a new stake in Blueprint Medicines in the second quarter valued at $557,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Blueprint Medicines by 8.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,792 shares of the biotechnology company's stock valued at $1,487,000 after acquiring an additional 1,064 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on BPMC shares. Wells Fargo & Company decreased their price objective on Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating for the company in a research note on Thursday, October 31st. StockNews.com upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a research report on Friday, November 8th. Guggenheim reissued a "buy" rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. HC Wainwright reaffirmed a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, November 15th. Finally, UBS Group assumed coverage on shares of Blueprint Medicines in a report on Thursday, October 24th. They issued a "neutral" rating and a $88.00 target price on the stock. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Blueprint Medicines has an average rating of "Moderate Buy" and an average target price of $122.11.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.